Premium
Clinical prognostic markers in stage IIIC melanoma
Author(s) -
Madu Max F.,
Schopman Jaap H.H.,
Berger Danique M.S.,
Klop Willem M.C.,
Jóźwiak Katarzyna,
Wouters Michel W.J.M.,
van der Hage Jos A.,
van Akkooi Alexander C.J.
Publication year - 2017
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24635
Subject(s) - medicine , interquartile range , melanoma , adjuvant therapy , ipilimumab , oncology , stage (stratigraphy) , retrospective cohort study , lymph node , adjuvant , survival analysis , surgery , cancer , immunotherapy , paleontology , cancer research , biology
Background Although the EORTC 18071‐trial has shown a clear survival benefit for adjuvant ipilimumab, accurately selecting patients for this toxic adjuvant therapy is important. We aimed to identify prognostic factors for death and disease recurrence in AJCC stage IIIC melanoma patients. Patients and Methods Retrospective analysis of patients who underwent lymph node dissection (LND) for stage IIIC melanoma in our institution between 2000 and 2016. Baseline characteristics, melanoma‐specific survival (MSS), and disease‐free survival (DFS) were assessed, and prognostic factors for recurrence and survival were analyzed using uni‐ and multivariable analysis. Results A total of 205 patients were included. Median follow‐up was 20 months (interquartile range 11‐43 months), median MSS was 28 months, and median DFS was 11 months. Five‐year MSS was 33% and 5‐year DFS was 23%. N3 (≥4 involved lymph nodes) and extracapsular extension (ECE) carried an increased risk of disease recurrence after LND and death by melanoma. Patients with both N3 and ECE had virtually no long‐term survival. Conclusions Although survival for patients with stage IIIC is poor in general, patients with both N3 disease and ECE constitute the group with the worst prognosis and should be considered for adjuvant therapy with ipilimumab or any other future effective adjuvant therapy (study).